Drugs / Pseudomonas aeruginosa
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05975151 | Oct 2023 → Aug 2025 | urinary bladder cancer | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07460297 | Apr 2025 → Jan 2028 expected | — | Jianyi Li | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pseudomonas aeruginosa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07460297 ↗ |
| Known as | PAP | “Using two to six vials of PAP（Inactivated Pseudomonas aeruginosa injection） preparation combined with 100ml of iodophor to soak the implant and irrigate the surgical cavity.” NCT07460297 ↗ |
| Route | Topical | “Using two to six vials of PAP（Inactivated Pseudomonas aeruginosa injection） preparation combined with 100ml of iodophor to soak the implant and irrigate the surgical cavity.” NCT07460297 ↗ |